ArticleMetabolic brain disease2026
Saikosaponin-d attenuates postpartum estrogen withdrawal-induced depressive symptoms by modulating glucocorticoid metabolism and inhibiting hippocampal NLRP3 inflammatory vesicle activation.
Article in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Postpartum depression (PPD) is a prevalent mental disorder affecting women worldwide. Radix Bupleuri, a traditional Chinese herb frequently used in PPD treatment formulations, contains saikosaponin-d (SSd) as one of its major bioactive constituents. Dysregulation of glucocorticoid metabolism and activation of the NLRP3 inflammasome have been implicated in the pathophysiology of depression. However, whether SSd alleviates PPD through modulation of these pathways remains unclear. In this study, we investigated the therapeutic effects and underlying mechanisms of SSd in a hormone-simulated PPD rat model. Following model establishment, anhedonia-like behavior was assessed using the sucrose preference test, while locomotor activity and anxiety-like behavior were evaluated using the open field test. Serum inflammatory cytokines levels were measured by ELISA, and hippocampal NLRP3 inflammasome-related proteins were examined by Western blot. SSd treatment significantly ameliorated PPD-induced behavioral deficits, as evidenced by increased sucrose preference and locomotor activity. Both SSd and fluoxetine (FLU) markedly suppressed the expression of NLRP3 inflammasome components (NLRP3, caspase-1) and reduced serum levels of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α). Notably, SSd—but not FLU—significantly decreased plasma corticosterone (CORT) and 11-dehydrocorticosterone (11-DHCORT) levels and was associated with altered 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activity, suggesting differential modulation of glucocorticoid metabolism. Additionally, SSd treatment coincided with increased estrogen receptor (ERα/ERβ) expression in key brain regions. Comprehensive analysis of these data suggests that SSd is associated with reduced neuroinflammation, restoration of glucocorticoid metabolic balance, and increased estrogen receptor expression, which may collectively contribute to the amelioration of PPD-like behaviors.
Indexed as
Identifiers
41925791What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.